chartmojo

SRPT regression play

Short
chartmojo Aktualisiert   
NASDAQ:SRPT   Sarepta Therapeutics, Inc.
3
100% pop should regress some
Kommentar:
important Duchens Muscular Dystrophy reversal/approval..small market however
Kommentar:
Frankly after researching this companies drug and Duchenne Muscular Dystrophy i find myself rooting for this company. This stock popped some 95% on an approval of their drug that delays the onset of the debilitating effects of this little known genetic disease in children. While there was and may be more regression opportunities in the price from a technical perspective, especially for a scalper like me, I'm hoping the company's stock actually ultimately goes to the moon and that those dedicated individuals involved in this company prosper because they deserve it.

Haftungsausschluss

Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.